News Contact Us Careers Get E-Mail alerts Search

ADMA Biologics, Inc.

  • Home
  • About Us
    • About ADMA Biologics
    • What We Do
    • Who We Are
      • Senior Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Compliance
  • Our Products
    • Products Overview
    • About Primary Immunodeficiency Disease (PI)
    • ASCENIV™
    • BIVIGAM®
    • Nabi-HB®
  • Our Pipeline
  • Immunotechnology
  • Plasma & IVIG
  • Medical Affairs
    • Medical Affairs Overview
    • Publications
  • Investors
    • Overview
    • Press Releases
      • Email Alerts
    • Company Info
      • Profile
      • Presentation
      • Management Team
      • Contacts
      • FAQ
    • Analyst Coverage
    • Events & Webcasts
    • Financial Info
      • Balance Sheets
      • Income Statement
      • Cash Flow
      • Financial Results
      • Annual Reports
    • Stock Info
      • Stock Data & Quote
      • Charts
      • Historical Data
    • SEC Filings
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Board Committees
      • Documents
  • News
  • Contact Us
  • Careers
  • Get E-Mail alerts
  • Search

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

News

See below for our most recent and archived news events.

Investors

Investors

  • Overview
  • Press Releases
    • Email Alerts
  • Company Info
    • Profile
    • Presentation
    • Management Team
    • Contacts
    • FAQ
  • Analyst Coverage
  • Events & Webcasts
  • Financial Info
    • Balance Sheets
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
  • Stock Info
    • Stock Data & Quote
    • Charts
    • Historical Data
  • SEC Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Documents
  • home Home
  • Investors
  • Press Releases
  • Press Releases

  • Email Alerts

Click below for current and archived news related to the company.

ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

Mar 05, 2020 6:59am EST

ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections

Mar 03, 2020 7:00am EST

ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock

Feb 24, 2020 7:00am EST

ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™

Feb 11, 2020 4:20pm EST

ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock

Feb 06, 2020 8:40pm EST

ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock

Feb 06, 2020 4:06pm EST

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook

Jan 09, 2020 7:00am EST

ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions

Jan 07, 2020 7:00am EST

ADMA Biologics Added to NASDAQ Biotechnology Index

Dec 17, 2019 7:08am EST

ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference

Nov 13, 2019 7:08am EST
RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...23
    Next
    About Us Our Products Our Pipeline Inmunotechnology Plasma & IVIG Medical Affairs Investors Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS

    © Copyright 2022 ADMA Biologics, Inc.
    Ramsey, NJ Offices 201-478-5552
    Boca Raton, FL Offices 561-989-5800
    info@admabio.com

    Best places to work
    Bio NJ

    2020 Innovator Award

    50 fastest companies
    2019 Fast 500 Deloitte
    Bio Florida

    Named 2019 Company of the Year